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The surgical treatment of epilepsy is one area of neurosurgery where patients can be conclusively
cured and have their lives radically changed. Based on the epidemiology (prevalence of 1%)
and natural history (20%-30% intractable) of epilepsy, there are likely at least 600,000 surgical
candidates in the US1. Weibe et al7 performed a randomized, controlled study in which patients
were randomly assigned to a surgical or non-surgical arm; the one-year seizure free rate was 58% in
the surgical group and 8% in the group treated medically. In a related study, in a two-year period,
36 epilepsy surgeries were performed, including 29 temporal lobectomies1. Among all patients,
30/36 were seizure-free and 5 almost seizure-free; within the temporal lobectomy subgroup, 27/29
were seizure free and 2/29 almost seizure-free.
Epilepsy surgery is standard of care when medications fail. Seizure-free rates following temporal
lobectomy are consistently 65% to 70% in adults and 68% to 78% in children3. Extratemporal
lobectomies, which are sometimes necessary in pediatric cases, are less successful (62% in children) 3.
Even where the patient fails to be seizure free, the rate of seizures is usually reduced. Failure of referral
to an epilepsy center, occurs too often and commonly results in delays in treatment. On average, there
is a mean duration of epilepsy of 18.8 years prior to surgical intervention7. Previous investigations
have demonstrated that the longer the duration of refractory epilepsy, the greater the deterioration
to cognition and overall functional ability, especially in the pediatric population3.
One reason for the delay is the difficulty in identifying refractory patients. This phenomenon is
interesting, as there is a generally accepted definition of medically intractable disease, refractory
to two drugs, more than two seizures per month over two years. Unfortunately, with 24 FDA
approved anti-epileptic drugs (AEDs), the concept of “medical intractability” has little practical
meaning. A limited survey of neurologists5 found that among respondents who prescribed single
drug regimens (not combinations), 52% required failure of three AEDs before declaring the case
intractable, and 19% did not give up until all AEDs had been tried. Among neurologists favoring
combination therapy, 77% required the patient to fail at least two combination regimens. Typically,
neurologists require a six-month wait to declare the patient seizure-free2. Kwan and Brodie (2001)6
demonstrated in a prospective study that once the patient fails the first appropriate AED trial, the
chance of seizure freedom is 14% with a second drug trial, and only 3% with a third drug or with
combinations.
Another factor in the delay of referral to epilepsy centers lies in the fact that many neurologists
are reluctant to consider epilepsy surgery as a necessary treatment option early in the course of
the disease. Among surveyed neurologists5, 57% required the epilepsy to last a minimum of two
years before referring for surgery. The disease also had to have reached a certain level of severity:
55% required the seizures to occur at least once a month before recommending surgery. Eleven
Table 1: Online references for epilepsy guidelines and clinical evidence
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Agency

Website

American Epilepsy Society

http://www.aesnet.org/go/practice/guidelines

American Association of Neurologists

http://www.aan.com/go/practice/guidelines

Cochrane Epilepsy Group

http://www.epilepsy.cochrane.org/en/index.html

Agency for Healthcare Research
and Quality

http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book
=hserta&part=A115370
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percent did not even discuss surgery with
their patients at all. In one surgical study, the
authors reported1 14% of patients who had
successfully undergone epilepsy surgery were
specifically advised by their neurologists not to
consider surgery as a treatment option.
A major stumbling block is the dissemination
of information. In the aforementioned survey,
the authors cited the Kwan and Brodie study,
but pointed out that none of the responding
neurologists seemed to base their determinations on the published Kwan and Brodie
results5. Less than half of the neurologists
discussed the likelihood of surgical outcomes
with their patients, and in that fraction there
was a uniform split between optimistic and
pessimistic expectations. It should be pointed
out that this split may reflect the distribution of
patients seen by each neurologist. Also, 47% of
the surveyed neurologists who did refer patients
to specialized epilepsy centers reported a lack of
appropriate clinical feedback from the surgical
center, which had an understandable effect on
their willingness to collaborate with the center
in the future.
However, guidelines have been published on
the web by both the American Epilepsy Society
and the American Association of Neurologists.
According to the American Academy of
Neurology Practice Parameter 4, for ‘‘surgical intervention to be considered practical,”
before years of uncontrollable seizures cause
irreversible psychosocial consequences, ‘‘it
must be offered before absolute pharmacoresistance is proven in most patients.” More
specific published guidelines state that referral
to a specialized epilepsy center is appropriate if
seizure control is not achieved within 9 months
by the general neurologist. The Cochrane
Collaboration also has a group dedicated to
evidence-based medicine in epilepsy, and the
Agency for Healthcare Research and Quality
has a public-domain text, Management of
Treatment-Resistant Epilepsy. Links to all four
of them are in Table 1.
The treatment of medically intractable epilepsy is very complicated. There are many
opinions and “recipes” available for success
and care has to be individualized to each

Functional

patient and their specific diseases. It does
seem prudent to have patients referred to epilepsy centers periodically in order to explore
developing treatment options in the future.
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At Jefferson Hospital for
Neuroscience, neurologist Michael
M. Moussouttas, MD, and nurse
Lauren Dougherty use the Jefferson
Expert Teleconsulting (JET) system to
consult with Robert H. Rosenwasser,
MD, FACS, Chair, Department of
Neurological Surgery (pictured on
monitor), who is at another location.

Pioneering Leading-Edge Treatments
Jefferson Hospital for Neuroscience staff have helped to
develop and/or have introduced to the region leadingedge treatments and technologies that reduce the need
for open brain surgery for stroke, brain aneurysms and
AVMs. Among them:
• Intra-arterial thrombolysis with tPA – pharmacological
blood clot-dissolving
• Mechanical thrombectomy devices – e.g., Merci
Retrieval System®
• Wingspan stent – FDA-approved mesh tube to open
blocked arteries in the brain after clot-dissolving drugs
have failed
• Coiling, gluing and stenting of brain aneurysms –
reduces need for open brain surgery

Announcing Jefferson’s Teleconsulting (JET) Robotic System for Help with
Diagnosis and Treatment of Time-Sensitive Neurovascular Diseases
“Time is brain” is the credo among healthcare
professionals for diagnosing and treating timesensitive neurovascular diseases, including arteriovenous malformations (AVMs), brain aneurysms and,
especially, stroke. The blood-clot busting medication
tissue plasminogen activator (tPA), for example, must
be administered to a patient having a stroke within
4.5 hours for best chance of functional recovery.
Timely performance of neurosurgical procedures
to remove AVMs and aneurysms are similarly
urgent. Yet many community hospitals have limited
experienced staff and technology to diagnose and
treat patients quickly and accurately.
Now, to provide sophisticated care and expertise
to patients at hospital emergency rooms in small
community hospitals in distant areas of eastern
Pennsylvania, south and central New Jersey, and
Delaware, Jefferson Hospital for Neuroscience
(JHN) in Philadelphia is launching Jefferson Expert
Teleconsulting (JET), the region’s first university-based
high-tech mobile robotic system for neuroscience.
“JET places all of our resources – among them, dualtrained neurosurgeons, advanced technology, and
leading-edge clinical trials in which we partner with the
National Institutes of Health – at the disposal of patients,
their families and physicians in need of a second, expert
opinion,” says Robert H. Rosenwasser, MD, FACS,
Professor and Chair, Department of Neurological
Surgery, JHN and Jefferson Medical College of Thomas
Jefferson University. “Its greatest value is for timely
diagnosis and application of treatment for time-sensitive
neurovascular diseases, especially stroke.”
Enhancing level of care
“We want to partner with hospitals in other
communities to help advance stroke care throughout

the region. As the leading provider of stroke care
in the region, we have an obligation to do that,”
adds Pamela Kolb, Vice President, Neuroscience
Service, JHN.
Supported by Thomas Jefferson University, a
leading academic center, JHN is the region’s only
dedicated hospital for neuroscience and leading,
most experienced and comprehensive center for
diagnosis and treatment of stroke and cerebrovascular
disease. JHN’s Acute Stroke Center is the largest such
facility, with more board-certified neurocritical care
physicians than most, in the greater Delaware Valley.
It is also a Joint Commission-accredited primary
stroke center.
“Stroke is the third-leading cause of death in the
United States but the leading cause of disability, by a
factor of five over any other disease,” Dr. Rosenwasser
notes. “Given its prevalence and time-sensitive nature,
it is alarming how few people receive treatment in the
appropriate amount of time. With JET, even hospitals
in remote areas can provide patients with expert
consultation and disposition of appropriate care from
an experienced neurologist or neurological surgeon
immediately in cases where every minute can make a
critical difference. It’s a very cost-effective approach to
providing 24/7 onsite coverage and expertise.”
How JET works
Each participating hospital is supplied with a mobile
robotic platform, manufactured by InTouch Health®
of Santa Barbara, CA, that enables the JHN Network
physician to be remotely present. JET’s panoramic
visualization system and easy-to-use control interface
afford physicians, patients and hospital staff a safe and
effective interactive experience.

InTouch’s remote presence devices are the first and
only with FDA approval. The robots allow direct
connection to medical devices such as electronic
stethoscopes, otoscopes and ultrasound to transmit
medical data to the remote physician.
“Should a patient arrive in the ER of a hospital that’s
located, say, three hours away from Jefferson and
either doesn’t have a neurologist or neurosurgeon
available or has a neurologist who needs to consult
with a neurosurgeon,” Dr. Rosenwasser, explains, “the
attending physician contacts JHN. The JHN Network
specialist on call then uses a laptop to connect to
the remote hospital via the robot, obtain a medical
history by speaking directly with the patient and/or
family members, examine the patient and determine
what therapy is immediately needed, in real time,
without delay. Finally, a decision is made either to
admit the patient to the local hospital’s Critical Care
Unit or transfer him or her to the Jefferson Acute
Stroke Center, by JeffSTAT, Jefferson’s transport
service, or the hospital’s own service.”
“Patients may not need to be transferred – they can
stay in their own community and be treated very
successfully there, thanks to this program,” says Ms.
Kolb. “And most patients want to stay close to home.
JET enables them to receive sophisticated medical
care without having to travel long distances.”
“It also serves as an educational program,” adds Dr.
Rosenwasser. “As a teaching center, JHN will use
JET to share our clinical protocols with participating
hospitals so that they can enhance stroke care within
their communities. On the other hand, should the
patient need an advanced neurosurgical procedure
[See sidebar], we can arrange for prompt transfer.”

JHN continues to set the standard worldwide
for state-of-the-art care for time-sensitive
neurovascular diseases. For more information
about these and other treatments, visit
www.JeffersonHospital.org/neuroscience.
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